RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Phase Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute at the US National Institutes of Health. The grant supports Phase I/II clinical development of innovative alpha-emitter labeled peptide, AlphaMedix^TM, for the therapy of somatostatin receptor positive neuroendocrine tumors.

RadioMedix successfully completed Phase I and Phase II NCI SBIR Contracts focused on the dose escalation and safety studies of AlphaMedix in PRRT (Peptide Receptor Radionuclide Therapy)-naïve neuroendocrine patients. The Phase II SBIR funding will be used to evaluate additional safety and efficacy of investigational drug and expanded clinical indications of AlphaMedix™. These clinical studies are done in collaboration with its business partner, Orano Med.

To read more please visit:

RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY

Source: RadioMedix